Open, Non Comparative Study Of Voriconazole In Slovak Patients With Very High Risk Of Developing An Invasive Fungal Infection (Ve-RIFI)
This study has been completed.
Sponsor:
Pfizer
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01137292
First received: June 2, 2010
Last updated: August 31, 2011
Last verified: August 2011
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
Assessment of safety and efficacy of voriconazole in real-life setting in the treatment of high risk patients with invasive fungal infections. The study is conducted in Slovakia only.
| Condition | Intervention |
|---|---|
|
Invasive Fungal Infections |
Drug: voriconazole (VFEND®) |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Voriconazole In High-Risk Patients With Invasive Fungal Infections In Slovakia. An Open, Prospective, Non-Comparative Study |
Resource links provided by NLM:
Further study details as provided by Pfizer:
Primary Outcome Measures:
- Number of Participants With Clinical and/or Mycological Efficacy by Response at the End of Treatment (EOT) Visit [ Time Frame: up to 2 weeks (EOT visit) ] [ Designated as safety issue: No ]Clinical, mycological responses: clinical cure, clinical improvement, no clinical cure, mycological cure, no mycological cure, and no mycological culture performed. Participants could have had more than one response. Responses were based on the investigator's judgement according to the Infectious Disease Society of America, European Conference on Infections in Leukemia, and European Committee on Antimicrobial Susceptibility Testing guidelines.
- Number of Participants With Clinical and/or Mycological Efficacy by Response at the Test-of-Cure Visit [ Time Frame: more than 2 weeks (Test-of-Cure visit) ] [ Designated as safety issue: No ]Clinical, mycological responses: clinical cure, clinical improvement, no clinical cure, mycological cure, no mycological cure, no mycological culture performed, death, and lost from follow-up. Participants could have had more than one response. Responses were based on the investigator's judgement according to the Infectious Disease Society of America, European Conference on Infections in Leukemia, and European Committee on Antimicrobial Susceptibility Testing guidelines.
- Number of Participants With Investigator's Satisfaction With the Efficacy of Voriconazole Assessment at the EOT Visit [ Time Frame: up to 2 weeks (EOT visit) ] [ Designated as safety issue: No ]Investigator's Satisfaction Responses: very good, good, moderate, poor. Responses were based on the investigator's judgement.
- Number of Participants With Investigator's Satisfaction With the Tolerability of Voriconazole Assessment at the EOT Visit [ Time Frame: up to 2 weeks (EOT visit) ] [ Designated as safety issue: No ]Investigator's Satisfaction Responses: very good, good, moderate, poor. Responses were based on the investigator's judgement.
| Enrollment: | 177 |
| Study Start Date: | April 2007 |
| Study Completion Date: | November 2009 |
| Primary Completion Date: | November 2009 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Active Treatment
Patients who are eligible for voriconazole treatment according to their physician decision.
|
Drug: voriconazole (VFEND®)
The use and dosage recommendations for voriconazole (VFEND®) will take place on the basis of the Summary of Product Characteristics (SmPC) and will be adjusted solely according to medical and therapeutic necessity. The formulation and dose will be managed by the treating physician according to the SmPC, disease and clinical situation. According to the SmPC, in the adults the treatment should be started with the loading dose of 6 mg/kg of voriconazole iv. every 12 hours (during the first 24 hrs) followed by the maintenance dose of 4 mg/kg BID. For peroral formulations, the initial dose should be depending on the weight of the patient 400 mg or 200 mg BID during the first 24 hrs, followed by the maintenance dose of 200 mg or 100 mg of voriconazole BID respectively For paediatric population (<12 years of age), there is no initial dose necessary. Depending on the formulation, the daily dosage should be in children 7 mg/kg iv. BID or 200 mg of voriconazole orally BID.
|
Eligibility| Ages Eligible for Study: | 2 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Male or female patients older than 2 years with invasive fungal infections.
Criteria
Inclusion Criteria:
- Male or female patient of age 2 years or older.
- High-risk patients with proven, probable or possible invasive fungal infection (IFI) according to the EORTC/MSG criteria.
- Patients indicated for secondary prophylaxis of invasive aspergillosis.
Exclusion Criteria:
- Patients with known hypersensitivity to voriconazole or to any of the excipients.
- Patients with contraindicated concomitant medications according to the SmPC.
- Children less than 2 years of age.
- Pregnancy and lactation.
Contacts and Locations More Information
Additional Information:
No publications provided
| Responsible Party: | Pfizer |
| ClinicalTrials.gov Identifier: | NCT01137292 History of Changes |
| Other Study ID Numbers: | A1501082 |
| Study First Received: | June 2, 2010 |
| Results First Received: | July 12, 2010 |
| Last Updated: | August 31, 2011 |
| Health Authority: | Slovakia: State Institute for Drug Control |
Keywords provided by Pfizer:
|
observational study voriconazole high-risk patients |
Additional relevant MeSH terms:
|
Mycoses Voriconazole Antifungal Agents Anti-Infective Agents Therapeutic Uses |
Pharmacologic Actions 14-alpha Demethylase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 22, 2013